Home › Companies › Design Therapeutics, Inc.

Design Therapeutics, Inc. (DSGN) proxy voting records

How asset managers voted at Design Therapeutics, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

TickerDSGN
CUSIP issuer number25056L
SEC CIK1807120

Recent shareholder votes

June 9, 2026 annual meeting (2025-2026 proxy season): 2 items in Design Therapeutics, Inc.'s official results (Form 8-K, filed June 11, 2026); lowest support 79% of votes cast (Elect Director: Simeon George, M.D.). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Season	Filed as	Ballot items	Asset managers
2025-2026	Design Therapeutics, Inc.	2	51

Explore Design Therapeutics, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.